Dan Vogl, MD, MSCE, University of Pennsylvania, Philadelphia, PA, reaffirms the role of selinexor, a selective inhibitor of nuclear export (SINE), for pre-treated patients with multiple myeloma. Speaking at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France, Dr Vogl recalls the Phase III BOSTON trial (NCT03110562), which showed the addition of selinexor with bortezomib and dexamethasone delivered superior response rates and progression-free survival (PFS) vs. bortezomib and dexamethasone alone. Dr Vogl also discusses the combinations available that can be varied depending on the patient.
